U.S. Markets closed
  • S&P 500

    4,166.45
    -55.41 (-1.31%)
     
  • Dow 30

    33,290.08
    -533.37 (-1.58%)
     
  • Nasdaq

    14,030.38
    -130.97 (-0.92%)
     
  • Russell 2000

    2,237.75
    -49.71 (-2.17%)
     
  • Crude Oil

    71.50
    +0.46 (+0.65%)
     
  • Gold

    1,763.90
    -10.90 (-0.61%)
     
  • Silver

    25.84
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1865
    -0.0045 (-0.3797%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3809
    -0.0115 (-0.8272%)
     
  • USD/JPY

    110.1500
    -0.0810 (-0.0735%)
     
  • BTC-USD

    35,605.44
    -22.38 (-0.06%)
     
  • CMC Crypto 200

    888.52
    -51.42 (-5.47%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    28,964.08
    -54.25 (-0.19%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna partners with Thermo Fisher to scale up COVID-19 vaccine production

·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

June 1 (Reuters) - Moderna Inc said on Tuesday it had entered into an agreement with Thermo Fisher Scientific for manufacturing and packaging its COVID-19 vaccine, as the U.S. vaccine maker looks to scale up production. 

  Under the terms, Moderna said Thermo Fisher's commercial manufacturing site in Greenville, North Carolina will be used to provide fill/finish manufacturing services and supply packaging for hundreds of millions of doses of the vaccine. 

  "The addition of Thermo Fisher to our network will support our efforts to scale up our manufacturing ability," Moderna's chief technical operations and quality officer, Juan Andres, said in a statement. 

  Earlier on Tuesday, Moderna filed for full U.S. approval of its COVID-19 vaccine for adults 

  Thermo Fisher said in March that it would work with Pfizer Inc and BioNtech SE to produce their COVID-19 vaccine in Italy. 

  In April, it announced a deal to buy contract researcher PPD Inc for $17.4 billion to add muscle to its pharmaceutical services business. (Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D'Silva)